Towards risk stratification and prediction of disease severity and mortality in COVID-19: Next generation metabolomics for the measurement of host response to COVID-19 infection
- PMID: 34851990
- PMCID: PMC8635335
- DOI: 10.1371/journal.pone.0259909
Towards risk stratification and prediction of disease severity and mortality in COVID-19: Next generation metabolomics for the measurement of host response to COVID-19 infection
Abstract
This study investigated the association between COVID-19 infection and host metabolic signatures as prognostic markers for disease severity and mortality. We enrolled 82 patients with RT-PCR confirmed COVID-19 infection who were classified as mild, moderate, or severe/critical based upon their WHO clinical severity score and compared their results with 31 healthy volunteers. Data on demographics, comorbidities and clinical/laboratory characteristics were obtained from medical records. Peripheral blood samples were collected at the time of clinical evaluation or admission and tested by quantitative mass spectrometry to characterize metabolic profiles using selected metabolites. The findings in COVID-19 (+) patients reveal changes in the concentrations of glutamate, valeryl-carnitine, and the ratios of Kynurenine/Tryptophan (Kyn/Trp) to Citrulline/Ornithine (Cit/Orn). The observed changes may serve as predictors of disease severity with a (Kyn/Trp)/(Cit/Orn) Receiver Operator Curve (ROC) AUC = 0.95. Additional metabolite measures further characterized those likely to develop severe complications of their disease, suggesting that underlying immune signatures (Kyn/Trp), glutaminolysis (Glutamate), urea cycle abnormalities (Cit/Orn) and alterations in organic acid metabolism (C5) can be applied to identify individuals at the highest risk of morbidity and mortality from COVID-19 infection. We conclude that host metabolic factors, measured by plasma based biochemical signatures, could prove to be important determinants of Covid-19 severity with implications for prognosis, risk stratification and clinical management.
Conflict of interest statement
R.S. Diaz, M.A. Budib, R. Ayache, R.M.S. Silva, F.C. Silva, S.S. Júnior, H.B.D. Pontes, A.C. Alvarenga, E.C. Arima, W.G. Martins, N.L.F. Silva, M.B. Salzgeber and A.M. Palma have no conflicts of interest to declare. P. D’Amora (consultation: Metabolomycs, Inc.; intellectual property rights (patent pending) Metabolomycs, Inc.; stockholder: Metabolomycs, Inc.). S.S. Evans (stockholder: Metabolomycs, Inc.). I.D.C.G. da Silva (consultation, Metabolomycs, Inc.; intellectual property (patent pending) Metabolomycs, Inc.; board director Metabolomycs, Inc.; stockholder: Metabolomycs, Inc.). R.A. Nagourney (intellectual property rights (patent pending) Metabolomycs, Inc.; board director: Nagourney Institute, board director Metabolomycs, Inc.; stockholder: Metabolomycs, Inc.). Robson Mateus Appel (RMA) was reimbursed for patient registration and sample collection costs by Metabolomycs, Inc. Dr. D’Amora and Dr da Silva of UNIFESP, receive consulting fees from Metabolomycs, Inc. for their cancer-related metabolomic research. We certify that the submission is original work and is not under review at any other publication.
Figures








Similar articles
-
Metabolic predictors of COVID-19 mortality and severity: a survival analysis.Front Immunol. 2024 May 10;15:1353903. doi: 10.3389/fimmu.2024.1353903. eCollection 2024. Front Immunol. 2024. PMID: 38799469 Free PMC article.
-
Immunometabolic signatures predict risk of progression to sepsis in COVID-19.PLoS One. 2021 Aug 30;16(8):e0256784. doi: 10.1371/journal.pone.0256784. eCollection 2021. PLoS One. 2021. PMID: 34460840 Free PMC article.
-
Metabolic Signatures Associated with Severity in Hospitalized COVID-19 Patients.Int J Mol Sci. 2021 Apr 30;22(9):4794. doi: 10.3390/ijms22094794. Int J Mol Sci. 2021. PMID: 33946479 Free PMC article.
-
Metabolomics in the Diagnosis and Prognosis of COVID-19.Front Genet. 2021 Jul 23;12:721556. doi: 10.3389/fgene.2021.721556. eCollection 2021. Front Genet. 2021. PMID: 34367265 Free PMC article. Review.
-
Could metabolomics drive the fate of COVID-19 pandemic? A narrative review on lights and shadows.Clin Chem Lab Med. 2021 Jul 30;59(12):1891-1905. doi: 10.1515/cclm-2021-0414. Print 2021 Nov 25. Clin Chem Lab Med. 2021. PMID: 34332518 Review.
Cited by
-
CD103+ dendritic cell-fibroblast crosstalk via TLR9, TDO2, and AHR signaling drives lung fibrogenesis.JCI Insight. 2025 Feb 18;10(6):e177072. doi: 10.1172/jci.insight.177072. JCI Insight. 2025. PMID: 39964756 Free PMC article.
-
Validation of a simple risk stratification tool for COVID-19 mortality.Front Med (Lausanne). 2022 Oct 11;9:1016180. doi: 10.3389/fmed.2022.1016180. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36304183 Free PMC article.
-
Metabolic Profiling at COVID-19 Onset Shows Disease Severity and Sex-Specific Dysregulation.Front Immunol. 2022 Jun 30;13:925558. doi: 10.3389/fimmu.2022.925558. eCollection 2022. Front Immunol. 2022. PMID: 35844615 Free PMC article.
-
Metabolomic profile of severe COVID-19 and a signature predictive of progression towards severe disease status: a prospective cohort study (METCOVID).Sci Rep. 2025 Feb 10;15(1):4963. doi: 10.1038/s41598-025-87288-x. Sci Rep. 2025. PMID: 39929875 Free PMC article.
-
Metabolomics as a powerful tool for diagnostic, pronostic and drug intervention analysis in COVID-19.Front Mol Biosci. 2023 Feb 15;10:1111482. doi: 10.3389/fmolb.2023.1111482. eCollection 2023. Front Mol Biosci. 2023. PMID: 36876049 Free PMC article. Review.
References
-
- Scarpellini B, Zanoni M, Sucupira MC, Truong HM, Janini LM, da Silva ID, et al.. Correction: Plasma Metabolomics Biosignature According to HIV Stage of Infection, Pace of Disease Progression, Viremia Level and Immunological Response to Treatment. PLoS One. 2017. Feb 24;12(2):e0173164. Erratum for: PLoS One. 2016 Dec 12;11(12):e0161920. doi: 10.1371/journal.pone.0173164 . - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous